Together4Cancer

New data shows TNBC outcomes differ by race not just because of access—but also biology. In community oncology, access is where we can act now, knowing that the biology is not helping. 🧬 Black women more often present with immune-cold TNBC—marked by macrophages, endothelial,…

🧵POSITIVE trial changes how we counsel young HR+ Breast cancer pts ✅74% conceived after pausing endocrine therapy, 65% even with AMH <0.5 ng/mL 🤰Low ovarian reserve ≠ No chance. 📉 LOR was the strongest predictor of reduced fertility 1/3 thebreastonline.com/article/S0960-… @OncoAlert

Evaluation and Treatment of Iron Deficiency for the Practicing Oncologist | @JCOOP_ASCO @OncoAlert @ASCO ascopubs.org/doi/10.1200/OP… Practical tips!!

A proposed treatment algorithm of patients with LR-MDS in 2025 mdpi.com/2072-6694/17/1… #mds @Dr_AmerZeidan

🚨 Common sense in HCC trials: Is PFS always a meaningful endpoint? Not really. If progression-free survival doesn’t translate into better quality of life, then it’s not a good endpoint — at least, not for all patients. @oncodaily @achoHematoYOnco

Wow. I am updating my profile to 18 year survivor instead of 17 years. I am here to show that early age onset of colorectal cancer can be a long and incredible life. I stand proud as a research advocate to show that the patient voice is important and not to be disregarded.

I wrote for #ASCOConnection about the duality of oncology—the quiet heaviness of being both oncologist and dad. The weight doesn’t go away, but you get better at carrying it—and finding meaning in the middle of the mess. What keeps you grounded? @ASCO lnkd.in/gxZ5Duuv

Treatment Algorithm: This is the algorithm we have used during our discussion w/ @Anand_88_Patel for AML! #OncTwitter #MedTwitter #HemeTwitter @OncUpdates

What Happens After Menopause (WHAM) Study results: RRSO in premenopausal BRCA1/2 carriers leads to declines in sexual function, mood, sleep, and bone density vs controls. MHT reduces some symptoms but only partially offsets bone loss. Cardiometabolic and cognitive outcomes stable…

The Women's Preventive Services Initiative (WPSI) moves beyond recommending just screening - it’s now prioritizing what happens after the mammogram, with an emphasis on health equity, system navigation, and real-world follow-up. This is a significant policy shift toward closing…

For multiple myeloma patients on bispecific antibodies, infectious risk remains high and persistent. Evidence now favors primary prophylaxis with IVIG/SCIG—initiating IgRT proactively, not tethered to IgG thresholds—given both the unreliability of IgG levels and the clear…

🚨 New modeling study shows LDCT is a cost-effective lung cancer screening strategy in India In high-risk adults (30–65 yrs), LDCT outperformed Chest X-Ray (CXR) and no screening: 🔹 QALYs: LDCT 23.7 vs CXR 19.8 vs No screening 13.4 🔹 ICER: ₹36,429 (below WTP threshold) 🔹…

The State of Blenrep: What Patients Should Know - MMRF. New PDUFA for blenrep. October 23. Fingers crossed. #mmsm themmrf.org/mmrf-blogs/the…

Just out! Current Risk stratification of all Plasma Cell Disorders. MGUS, SMM, Myeloma, Amyloidosis. We paid Open Access fees so you can download and read freely! Lots of Tables. Bookmark. @ZanwarSaurabh @myelomaMD @LeukemiaJnl Link: nature.com/articles/s4137…

📌 Real-world data sheds light on teclistamab use in multiple myeloma patients with renal impairment (RI)—a group often excluded from trials. In 384 patients, 21% had RI (CrCl <40 mL/min), including those on dialysis. 💡 Despite higher cytopenias, efficacy (ORR 52%) and safety…

In pooled data from 4 pivotal trials (RESONATE, RESONATE-2, iLLUMINATE, HELIOS), baseline statin use in CLL/SLL patients was independently associated with: 🔹 Improved OS (aHR 0.62) 🔹 Longer PFS (aHR 0.74) 🔹 Reduced cancer-specific mortality (aHR 0.39) 🔹 No increases in grade…

We appreciate the feedback on the table we had shared! Made some changes based on the recs/step-up dosing for Epcoritamab (as we also need this for Glofit) 🙏🏽🙏🏽! Here is the updated version 👇👇 #HemeTwitter #OncTwitter #MedTwitter #ChallengingCases

In the AQUILA trial, daratumumab: -Delayed progression to active myeloma -Delayed time to needing full myeloma therapy -Better overall survival -Preserved quality of life nejm.org/doi/full/10.10… @nejm @thanosdimop @PlasmaCellPete @SagarLonialMD The latest NCCN guidelines…

🧠 New recommendations alert! CAYA cancer survivors face long-term kidney risks. 🔍 The International Late Effects of Childhood Cancer Guideline Harmonization Group recommends routine, uniform long-term follow-up care for CAYA survivors of cancer at risk of nephrotoxicity: •…

EGFR-mutant NSCLC has seen transformative change with targeted TKIs improving survival and reducing toxicity compared to traditional therapies. Recent advances include: • TKI integration into early and locally advanced disease. • Phase 3 trials of combination approaches in…